FCPR03 is a novel potent, selective PDE4 inhibitor with IC50 of 60, 31 and 47 nM for PDE4CAT (PDE4 catalytic domain), PDE4B1 and PDE4D7, respectively.
FCPR03 displays >2,000-fold selectivity over other PDEs.
FCPR03 effectively increases the production of cAMP, promotes CREB phosphorylation, and inhibits NF-κB activation both in vitro and in vivo.
FCPR03 displays anti-neuroinflammation potential, promising antidepressant-like effects in vivo.
